Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Table 5 Acute exacerbations at 12 months according to predicted FVC% at baseline

	Total N = 204	FVC < 50% N = 22	FVC 50–80% N = 152	FVC > 80% N = 30	p-value
Patients who experienced an AE-IPF during the study, n (%)	22 (10.8%)	6 (27.3%)	13 (8.6%)	3 (10.0%)	0.0333
Number of AE-IPF per patient^a, mean (SD)	0.14 (0.44)	0.41 (0.80)	0.11 (0.38)	0.10 (0.31)	0.0255
Number of exacerbations by patient—group^a, n (%)					0.0540
0 exacerbations	182 (89.2%)	16 (72.7%)	139 (91.4%)	27 (90.0%)
1 exacerbation	18 (8.8%)	4 (18.2%)	11 (7.2%)	3 (10.0%)
> 1 exacerbations	4 (2.0%)	2 (9.1%)	2 (1.3%)	0 (0.0%)
Number of AE-IPF per patient with AE^b , mean (SD)	1.27 (0.63)	1.50 (0.84)	1.23 (0.60)	1.00 (0.00)	0.4562
Duration of AE-IPF (in days), mean (SD)	16.50 (18.38)	12.67 (6.32)	20.56 (23.15)	6.33 (5.03)	0.2259

In bold, p-values < 0.05
22 patients reported 28 AE-IPF events through the study period. AE-IPF acute exacerbation of IPF, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, SD standard deviation
^aOver all patients (n = 204). Patient without exacerbation was imputed 0 exacerbations
^bOver the patients with exacerbations (n = 22)

ISSN: 1465-993X